SCHEMBL6322602

SCHEMBL6322602

Cc1ccc(CNC(=O)c2c(-c3ccc(C)o3)noc2N)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.49
HPGD P15428 4/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ADORA2A P29274 3/20 0.42
ADORA1 P30542 3/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
GAA P10253 1/20 0.42
POLB P06746 3/20 0.41
THRB P10828 1/20 0.41
MAPT P10636 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
ADORA2B P29275 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317800 0.91 GAA (0.53) KMT2AHPGDALDH1A1MEN1KDM4E
SCHEMBL6317624 0.89 HPGD (0.59) KMT2AHPGDALDH1A1MEN1KDM4E
SCHEMBL6324100 0.89 CA1 (0.53) KMT2AHPGDALDH1A1MEN1KDM4E
SCHEMBL6317613 0.88 LSS (0.42) KMT2AHPGDADORA2AADORA1MAPT
SCHEMBL6314500 0.87 ALDH1A1 (0.48) KMT2AHPGDALDH1A1KDM4EADORA2A
SCHEMBL6316430 0.86 S1PR3 (0.43) KMT2AHPGDALDH1A1ADORA2AADORA1
SCHEMBL6314998 0.86 MAPT (0.44) ALDH1A1ADORA2AADORA1POLBMAPT
SCHEMBL6321626 0.86 ADRB2 (0.47) HPGDALDH1A1ADORA2AADORA1MAPT
SCHEMBL6318079 0.84 L3MBTL1 (0.48) KMT2AHPGDALDH1A1MEN1KDM4E
SCHEMBL6317141 0.84 GAA (0.59) KMT2AHPGDALDH1A1MEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 KMT2A 1089/4885HPGD 2923/4885ALDH1A1 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.